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2214-0247/Copyright ª 2014, TaiwanAbstract Mutations in the quinolone resistance-determining regions (QRDRs) of gyrA, gyrB,
parC, and parE have been characterized among the 232 isolates of ciprofloxacin (CIP)-resistant
Pseudomonas aeruginosa. As expected, no mutations in the QRDRs of four target genes were
detected in the CIP-susceptible isolates of P. aeruginosa. It was noted that P. aeruginosa
showing no mutation in the QRDRs of target genes were frequently found in isolates with a
CIP in minimal inhibitory concentration (MIC) Z 2 mg/mL than those of isolates with a CIP in
MIC 4 mg/mL. The prevalence of P. aeruginosa with no mutations in the QRDRs of target genes
is higher in isolates only resistant to CIP than in isolates resistant to CIP and other drugs. Dou-
ble mutations occurring in gyrA and parC genes associated with a high-level resistance to CIP in
MICs 4 mg/mL were found in 101 out of 176 isolates. Furthermore, mutations in parC and parE
joined with mutation in gyrA were commonly found in P. aeruginosa highly resistant to CIP.
Copyright ª 2014, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.of Medical Laboratory
f Health Sciences, Kaohsiung
-Chuan 1st Road, Kaohsiung
tw (C.-F. Peng).
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Genomic Medicine and BiomarkerIntroduction
Because of the possession of a high level in intrinsic and
acquired resistance, therapeutic challenge is of great
concern in the treatment of infectious diseases caused by
multidrug-resistant Pseudomonas aeruginosa.1 Current an-
tibiotics used for multidrug-resistant P. aeruginosa in-
fections are limited to fluoroquinolones, aminoglycosides,
and carbapenems. Ciprofloxacin (CIP) has been shown to be
effective in the treatment of serious infections with P.Society. Published by Elsevier Taiwan LLC. All rights reserved.
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the dual targets of DNA gyrase and topoisomerase IV.2
Bacterial DNA gyrase and topoisomerase IV are the major
targets of quinolone antimicrobial agents. Therefore, mu-
tations in the quinolone resistance-determining regions
(QRDRs) of gyrA, gyrB, parC, and parE genes were found to
be associated with fluoroquinolone resistance in most
bacterial species including P. aeruginosa.3,4 In Taiwan, P.
aeruginosa showed 6.2e16.1% resistance to CIP.5 As regards
resistance to CIP associated with target gene mutations in
the QRDRs, little information is known about P. aeruginosa
in Taiwan. The aim of this study is to demonstrate the
molecular mechanism of CIP resistance in P. aeruginosa due
to target gene mutations. The point mutations involved in
the QRDRs of DNA gyrase in gyrA and gyrB genes and
topoisomerase IV in parC and parE genes among CIP-
resistant P. aeruginosa isolates were also characterized.
Materials and methods
Bacterial strain
In this study, a total of 262 nonduplicate clinical isolates of
P. aeruginosa used to screen mutations in the QRDRs of
gyrA, gyrB, parC, and parE genes, including 30 isolates
susceptible to CIP (MICs of 1 mg/mL), 56 isolates
intermediate-resistant to CIP, with MICZ 2 mg/mL, and 176
isolates highly resistant to CIP, with MICs ranging from 4 mg/
mL to 125 mg/mL. Among the 232 isolates of CIP-resistant
P. aeruginosa, 48 isolates showed resistance to CIP only,
and the remaining 184 isolates were simultaneously resis-
tant to CIP and other drugs such as ceftazidime, mer-
openem, gentamicin, amikacin, or piperacillin. These
isolates were obtained from Kaohsiung Medical University
Hospital, Kaohsiung, Taiwan in 2010e2012. The antibiotic
susceptibility test of minimal inhibitory concentrations
(MICs) for all isolates was conducted using the VITEK 2
system (bioMe´rieux, Marcy I’Etoile, France).
Polymerase chain reaction techniques and BLAST
program
Bacterial genomic DNA was extracted using a Genomic DNA
Purification Kit (Promega Biosciences Inc., San Luis Obispo,
CA, USA). All isolates of P. aeruginosawere screened for gyrA,
gyrB, parC, and parE genes by polymerase chain reaction
(PCR) amplification using specific primers against bacterial
DNA template as previously described.6,7 Primers gyrA-F (50-
AGTCCTATCTCGAC TACGCGAT-30) and gyrA-R (50-AGTC
GACGGTTTCCTTTTCCAG-30) were used to amplify 324 bp of
the gyrA gene (accession no. AAG06556). Primers gyrB-F (50-
TGCGGTGGAACAGG AGATGGGCAAGTAC-30) and gyrB-R (50-
CTGGCGGAAGAAGAAGGTCAAC AGCAGG GT-30) were used to
amplify 483 bp of the gyrB gene (accession no. AAG03394).
Primers parC-F (50-CGAGCAGGCCTATCTGAACTAT-30) and
parC-R (50-GAAGGACTTGGGATC GTCCGGA-30) were used to
amplify 282 bp of the parC gene (accession no. AAG08349).
Primers parE-F (50-CGGCGTTCGTCTCGGGCGTGGTGAAGGA-
30) and parE-R (50-TCGAGG GCGTAGTAGATGTCCTTGCCGA-30)
were used to amplify 564 bp of the parE gene (accession no.
AAG08352). The amplification techniques were performedusing Fast-Run Taq TM Master kit (Protech Technology En-
terprises Co., Ltd, Taipei, Taiwan). The PCR reactions were
performed on a DNA thermalcycler (Gradient master cycler;
Eppendorf, USA) for 35 cycles, each cycle consisting of 1
minute at 94C for denaturation, 30 seconds at 55C (for gyrA
and parC genes) or 60C (for gyrB and parE genes) for
annealing, and 1 minute at 72C for polymerization. The PCR
products were purified with a PCR-M Clean up System Kit
(Viogene, Sunnyvale, CA, USA) and then directly sequenced
on both strands by means of the primer walking sequence
strategy. The DNA sequencing analysis was compared with
those available in the sequence of wild-type P. aeruginosa
PAO1 (accession no. NC-002516) at GenBank data using the
BLAST suite of programs (http://www.ncbi.nlm.nih.gov/
BLAST).Results
The relationship between mutations of QRDRs target
genes and antibiotic resistance patterns in P. aeruginosa
isolates are listed in Table 1. A total of seven types of
mutation in QRDRs target genes were detected in CIP-
resistant P. aeruginosa isolates. In general, double mu-
tations of gyrAeparC genes (Type I) were the most
frequently found in CIP-resistant P. aeruginosa isolates
tested (43.1%, 100/232). The majority of CIP-resistant P.
aeruginosa isolates (76.7%, 178/232) showed single mu-
tation in gyrA gene (Types I, II, III, and V). Mutations in
gyrB gene (Type IV) were only found in 10 (4.3%) out of
232 CIP-resistant P. aeruginosa. Single parC mutation
(Type VI) was also only found in 1.1% (2/184) of P. aeru-
ginosa isolates resistant to CIP together with other
selected drugs, but did not occur in isolates only resistant
to CIP.
The mutation frequency of the QRDR target genes in P.
aeruginosa isolates showing resistance to CIP together with
other drugs (79.3%, 184/232) was higher than that in iso-
lates resistant only to CIP (20.7%, 48/232). The former
isolates showed a higher incidence (51.1%, 94/184) of Type I
QRDR mutations of gyrAeparC genes than that of the latter
isolates (12.5%, 6/48). Isolates of CIP-resistant P. aerugi-
nosa showing no mutations in QRDR target genes were
categorized as Type VII QRDR mutations. Among the Type
VII QRDR mutations, the percentage of P. aeruginosa iso-
lates showing resistance only to CIP (37.5%, 18/48) was
higher than that of isolates resistant to CIP together with
other drugs (13.0%, 24/184). Furthermore, mutation in
QRDR target genes of gyrA, gyrB, parC, and parE does not
occur simultaneously in the P. aeruginosa isolates tested.
From our results, mutations of QRDRs were not found in the
sequence area in gyrA, gyrB, parC, and parE genes among
these 30 CIP-susceptible (MICs 1 mg/mL) P. aeruginosa
isolates (data not shown).
The mutation of QRDR target genes leading to amino
acid substitutions sorted by CIP in MIC values for P. aeru-
ginosa isolates are listed in Table 2. A significant difference
was detected in the frequency of QRDR mutations among
CIP-resistant P. aeruginosa between high-level resistant
isolates (MIC  4 mg/mL; 75.8%, 176/232) and low-level
resistant isolates (MIC Z 2 mg/mL; 24.1%, 56/232). With
respect to Type I QRDR mutation, double mutations of
Table 1 The relationship between mutations of the quinolone resistance-determining regions and antibiotic resistance pat-
terns in Pseudomonas aeruginosa isolates.
Type of
mutation
Mutations of Antibiotic resistance patterns Total (%)
DNA gyrase Topoisomerase IV Resistant to
CIP only
Multidrug-resistant
to CIP and other drugs selected
p
gyrA gyrB parC parE No. (%) No. (%)
Type I ＋  ＋  6 (12.5) 94 (51.1) <0.01 100 (43.1)
Type III ＋    18 (37.5) 40 (17.2) <0.05 58 (25.0)
Type IV ＋   ＋ 4 (8.3) 12 (6.5) NS 16 (6.9)
Type V  ＋   2 (4.2) 8 (4.3) NS 10 (4.3)
Type VI ＋  ＋ ＋ 0 4 (2.2) NS 4 (1.7)
Type VII   ＋  0 2 (1.1) NS 2 (0.09)
Type II     18 (37.5) 24 (13.0) <0.05 42 (18.1)
Total (%) 48 (20.7) 184 (79.3) <0.01 232
Statistical significance (p) was calculated using the Pearson Chi-square test in terms of the number of strains.
þ Z mutation;  Z no mutation; CIP Z ciprofloxacin; NS Z not statistically significant.
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stitutions were mostly responsible for the high-level resis-
tance to CIP (43.1%, 100/232). The gyrAeparC mutation
was commonly found in isolates high-level resistant to CIP
(52.8%, 93/176) than in isolates low-level resistant to CIP
(10.7%, 6/56). It was apparent that P. aeruginosa with no
mutation in QRDR target genes (Type VII) was frequently
found in isolates low-level resistant to CIP (42.9%, 24/56)
than in isolates high-level resistant to CIP (10.2%, 18/176).
The most prevalent mutation in the gyrA gene was the
Thr83Ile substitution among isolates harboring gyrAeparC
mutation (Type I QRDR mutation; 99.0%, 98/99). By
contrast, variable amino acid substitutions in the parC gene
with Gly85Cys, Ser87Leu, Ser87Trp, and Glu91Lys were
found. Single gyrA mutations in isolates of Type II QRDR
mutation were frequently identified at amino acid Thr83Ile
substitution (74.1%, 40/54). However, a variety of amino
acid substitutions occurring at position 87 in gyrA mutations
with Asp87Asn, Asp87His, Asp87Tyr, and Asp87Gly were
found. There was no remarkable difference in mutation
frequency in the gyrA gene among P. aeruginosa between
isolates low-level resistant to CIP (32.1%, 18/56) and iso-
lates high-level resistant to CIP (21.0%, 37/176). The Type
III QRDR mutation in gyrAeparE genes was more frequently
found in P. aeruginosa isolates with a CIP in MIC 4 mg/mL
(93.7%, 15/16) than in isolates intermediate-resistant to CIP
(MICZ 2 mg/mL; 6.3%, 1/16). Among the isolates with Type
III QRDR mutation of gyrAeparE genes, the parE gene
showed a highly variable locus within the amino acid sub-
stitutions, and most of the gyrA also showed a Thr83Ile
substitution (93.7%, 15/16).
Among the Type IV QRDR mutations of the gyrB gene, all
10 isolates had only one type mutation of Ser466Phe sub-
stitution. These isolates with Type-IV QRDR mutation were
frequently associated with high-level resistance to CIP
(80%, 8/10). Only four out of 232 isolates (1.8%) belonged to
Type V QRDR mutation of gyrAeparCeparE genes. It
exhibited two type mutations of gyrA (Thr83Ile)eparC
(Ser87Leu)eparE (Ser457Arg) and gyrA (Thr83Ile)eparC
(Ser87Leu)eparE (Glu459Val). Finally, there are only twoisolates harboring Type VI QRDR mutation in the parC gene.
However, these two isolates have the same mutation of the
parC gene at Ser87Leu with a MIC 4 mg/mL.Discussion
Our results indicate that these four QRDR target genes of
DNA gyrase and topoisomerase IV are highly associated with
resistance to CIP in P. aeruginosa isolates. However, P.
aeruginosa isolates showing no mutation in QRDR target
genes was more frequently found in lower CIP-resistant
isolates than those in higher CIP-resistant isolates. These
results suggested that low-level resistance to CIP in P.
aeruginosa isolates is associated with target gene muta-
tions in QRDRs and other additional different efflux pump
systems.8,9 Moreover, CIP-resistant P. aeruginosa isolates
showing mutations in QRDR target genes were less
frequently found in isolates resistant only to CIP than in
isolates resistant to CIP together with other drugs such as
ceftazidime, meropenem, gentamicin, amikacin, or piper-
acillin. These results suggested that mutations within gyrA,
gyrB, parC, and parE genes were associated with resistance
not only to CIP but also to other selected drugs.10
It was noted that CIP-resistant P. aeruginosa isolates
showed the highest frequency of mutation in the gyrA gene
among these four QRDR target genes. Although mutations in
gyrAeparC, gyrAeparE, and gyrAeparCeparE, individually,
associated with high-level resistance to CIP, a single muta-
tion in gyrA was responsible for the variable MIC values of
resistance to CIP in P. aeruginosa isolates.11 In other studies,
98.1% of mutation at Thr83Ile occurring in the gyrA gene,
and double mutations in the gyrA gene have been described
at Thr83Ile and Asp87Asn or Tyr.7,11e13 In our isolates, gyrA
gene mutation at Thr83Ile conferred high-level resistance in
P. aeruginosa (MICs  4 mg/mL), and mutation in gyrA at the
codon 87 position contributed to the low-level resistance to
CIP (MIC Z 2 mg/mL). CIP-resistant isolates carrying muta-
tions in the gyrB gene at codons 464, 466, 468, and 475
positions have been demonstrated in other CIP-resistant
Table 2 The correlation of amino acid substitution in mutations of the quinolone resistance-determining regions and CIP
resistance in MIC (mg/mL) among Pseudomonas aeruginosa isolates.
Type of
mutation
Amino acid substitution of No. of isolates resistant
to CIP with MIC (mg/mL)
Total (%)
DNA gyrase Topoisomerase Ⅳ 2 4 Subtotal
gyrA gyrB parC parE No. No.
Type I Thr83Ile d Ser87Leu d 0 78 78 100 (43.1)
Thr83Ile d Glu91Lys d 3 7 10
Thr83Ile d Gly85Cys d 2 4 6
Thr83Ile d Ser87Trp d 0 3 3
Thr83Ile d Ser87Leu
Gly85Cys
d 0 2 2
Asp87Tyr d Ser87Leu d 1 0 1
Type II Thr83Ile d d d 10 36 46 58 (25.0)
Asp87Asn d d d 4 3 7
Asp87His d d d 3 0 3
Asp87Tyr d d d 1 0 1
Asp87Gly d d d 1 0 1
Type III Thr83Ile d d Leu501Phe 0 3 3 16 (6.9)
Thr83Ile d d Ser457Gly 0 3 3
Thr83Ile d d Glu453Asp 0 3 3
Thr83Ile d d Asp419Asn 0 2 2
Thr83Ile d d Lys388Glu 0 1 1
Thr83Ile d d Glu459Val 0 2 2
Thr83Ile d d Val460Phe
Ala473Val
0 1 1
Asp87Asn d d Ala473Thr 1 0 1
Type IV d Ser466Phe d d 2 8 10 10 (4.3)
Type V Thr83Ile d Ser87Leu Ser457Arg 2 2 4 (1.7)
Thr83Ile d Ser87Leu Glu459Val 2 2
Type VI d d Ser87Leu d 2 0 2 2 (0.09)
Type VII d d d d 24 18 42 42 (18.1)
Total 56 176 232 232
d Z no mutation; CIP Z ciprofloxacin; MIC Z minimal inhibitory concentration.
82 Y.-T. Wang et al.isolates of P. aeruginosa.10e13 However, single mutation in
gyrB gene with the same amino acid substitution at
Ser466Phe was detected in this study. Although single mu-
tation in the parC gene encoded moderate resistance to CIP,
parC mutation together with mutations in gyrA or in com-
bination with gyrAeparE genes were commonly associated
with high resistance to CIP in our P. aeruginosa isolates.14 As
described in previous reports, mutations in the parE gene
for fluoroquinolone resistance was rare and showed highly
variable profiles of amino acid substitutions.11,15 Noticeably,
three novel mutation sites at Lys388Glu, Leu501Phe, and
Val460Ala in the parE gene are first reported in this study,
and these three mutation sites mediated high-level resis-
tance to CIP. Furthermore, mutations in parE linking
simultaneously with mutation in gyrA or gyrAeparC would
encode high-level resistance to CIP in P. aeruginosa isolates.
In conclusion, gyrA is the primary target gene in the
QRDR mutation to mediate CIP resistance in P. aeruginosa
isolates. Double mutations of gyrAeparC or gyrAeparE, and
triple mutations of gyrAeparCeparE were mostly associ-
ated with high-level resistance to CIP in P. aeruginosa iso-
lates. The diversity of mutations in parC and parE geneswas more frequently found than that of gyrA and gyrB
genes in our P. aeruginosa isolates.
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